Hypoglycemia Clinical Trials Surge as 15+ Companies Advance 20+ Therapies across Multiple Development Stages, analyses DelveInsight

Hypoglycemia Clinical Trials

“Hypoglycemia Pipeline Insight, 2026″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypoglycemia Market.

The Hypoglycemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Get a Free Sample PDF Report to know more about Hypoglycemia Pipeline Therapeutic Assessment – https://www.delveinsight.com/report-store/hypoglycemia-pipeline-insight

Some of the key takeaways from the Hypoglycemia Pipeline Report:

• Hypoglycemia companies across the globe are diligently working toward developing novel Hypoglycemia treatment therapies with a considerable amount of success over the years.
• Hypoglycemia companies working in the treatment market are Twist Bioscience, MBX Biosciences, Eiger BioPharmaceuticals, Hanmi Pharmaceutical, Zealand Pharma, Vogenx, Inc., RECORDATI GROUP, Zucara Therapeutics, Vertex Pharmaceutical, Hanmi Pharmaceutical, and others, are developing therapies for the Hypoglycemia treatment

• Emerging Hypoglycemia therapies in the different phases of clinical trials are- Zimislecel, Imapextide, ZT-01, Avexitide, OPF-310, CRG-002, CFTX-2034, Mizagliflozin, Pasireotide Diaspartate, Retatrutide, and others are expected to have a significant impact on the Hypoglycemia market in the coming years.
• In March 2026, Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that the last participant has been randomized and dosed in the pivotal Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist with U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation in post-bariatric hypoglycemia (PBH). LUCIDITY is a 16-week, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of avexitide in adults with PBH following Roux-en-Y gastric bypass (RYGB) surgery. Participants who complete the 16-week double-blind period are eligible to enter a 32-week open-label extension period. The trial has enrolled 78 participants, with topline data readout anticipated in Q3 2026. If approved, commercial launch of avexitide is anticipated in 2027.
• In December 2024, Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) has unveiled the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational first-in-class GLP-1 receptor antagonist aimed at treating post-bariatric hypoglycemia (PBH). The trial will assess the FDA-agreed primary outcome of reducing hypoglycemia events and will maintain similar inclusion and exclusion criteria as previous Phase 2 studies of avexitide in PBH. Amylyx plans to begin dosing the first participant in early 2025, complete recruitment within the same year, and release topline results in 2026.
• In November 2024, MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced the completion of the final subject’s last visit in its Phase 1 trial of MBX 1416. This study, which evaluated single and multiple ascending doses, focuses on MBX 1416, a long-acting GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia (PBH).

Hypoglycemia Overview

Hypoglycemia is a condition characterized by an abnormally low level of glucose (sugar) in the blood. Glucose is the primary energy source for the body’s cells, especially the brain, and maintaining normal blood glucose levels is essential for proper bodily function.

Explore the latest Hypoglycemia pipeline insights 2026, including emerging therapies, clinical trials, and market opportunities. Stay ahead in Hypoglycemia Clinical Trials

Emerging Hypoglycemia Drugs Under Different Phases of Clinical Development Include:

• TB 222 023: Twist Bioscience
• MBX 1416: MBX Biosciences
• Avexitide: Eiger BioPharmaceuticals
• HM 15136: Hanmi Pharmaceutical
• Dasiglucagon: Zealand Pharma
• Mizagliflozin: Vogenx, Inc.
• Pasireotide Diaspartate: RECORDATI GROUP
• ZT-01: Zucara Therapeutics
• VX-880: Vertex Pharmaceutical
• HM15136: Hanmi Pharmaceutical

Hypoglycemia Pipeline Outlook

Zimislecel: Vertex Pharmaceuticals Incorporated

Zimislecel (previously known as VX-880) is an allogeneic, stem cell-derived therapy composed of fully differentiated insulin-producing islet cells, developed using proprietary technology. It is intended for individuals with Type 1 Diabetes (T1D) who experience impaired awareness of hypoglycemia along with severe episodes. The therapy is administered via infusion into the hepatic portal vein and requires immunosuppressive treatment to prevent rejection of the transplanted islet cells. Currently, Zimislecel is in Phase III clinical development for the treatment of hypoglycemia.

Imapextide: MBX Biosciences

Imapextide (MBX 1416) is an investigational, long-acting GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia (PBH). The therapy works by blocking excessive GLP-1 secretion after meals, which is known to trigger hyperinsulinemia and subsequently lead to hypoglycemia. By reducing GLP-1-driven insulin spikes, Imapextide aims to regulate insulin levels, increase blood glucose, and minimize both the frequency and severity of hypoglycemic events. It is designed for convenient once-weekly dosing and is currently in Phase II clinical trials.

ZT-01: Zucara Therapeutics

ZT-01, developed by Zucara Therapeutics, is a first-in-class, once-daily therapy designed to prevent insulin-induced hypoglycemia in patients undergoing insulin treatment. The drug functions by inhibiting somatostatin, a hormone that suppresses glucagon release during hypoglycemic episodes in individuals with insulin-dependent diabetes. By restoring the body’s natural glucagon response, ZT-01 aims to prevent hypoglycemia and significantly improve disease management as well as patient quality of life. The therapy is currently in Phase II clinical development.

Hypoglycemia Route of Administration

Hypoglycemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Hypoglycemia Molecule Type

Hypoglycemia Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Hypoglycemia Pipeline Therapeutics Assessment

• Hypoglycemia Assessment by Product Type
• Hypoglycemia By Stage and Product Type
• Hypoglycemia Assessment by Route of Administration
• Hypoglycemia By Stage and Route of Administration
• Hypoglycemia Assessment by Molecule Type
• Hypoglycemia by Stage and Molecule Type

DelveInsight’s Hypoglycemia Report covers around 20+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Hypoglycemia product details are provided in the report. Download the Hypoglycemia pipeline report to learn more about the emerging Hypoglycemia therapies

Some of the key companies in the Hypoglycemia Therapeutics Market include:

Key companies developing therapies for Hypoglycemia are – Amphastar Pharmaceuticals, Eiger BioPharmaceuticals, Eli Lilly, Novo Nordisk, Xeris Pharmaceuticals, Fresenius Kabi, Zeal and Pharma, and others.

Hypoglycemia Pipeline Analysis:

The Hypoglycemia pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Hypoglycemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypoglycemia Treatment.
• Hypoglycemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hypoglycemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypoglycemia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hypoglycemia drugs and therapies

Hypoglycemia Pipeline Market Drivers

• Rising prevalence of Hypoglycemia, Rising awareness, are some of the important factors that are fueling the Hypoglycemia Market.

Hypoglycemia Pipeline Market Barriers

• However, High cost of clinical trial research, increasing side effects associated with treatment and other factors are creating obstacles in the Hypoglycemia Market growth.

Scope of Hypoglycemia Pipeline Drug Insight

• Coverage: Global
• Key Hypoglycemia Companies: Twist Bioscience, MBX Biosciences, Eiger BioPharmaceuticals, Hanmi Pharmaceutical, Zealand Pharma, Vogenx, Inc., RECORDATI GROUP, Zucara Therapeutics, Vertex Pharmaceutical, Hanmi Pharmaceutical, and others
• Key Hypoglycemia Therapies: TB 222 023, MBX 1416, Avexitide, HM 15136, Dasiglucagon, Mizagliflozin, Pasireotide Diaspartate, ZT-01, VX-880, HM15136, and others
• Hypoglycemia Therapeutic Assessment: Hypoglycemia current marketed and Hypoglycemia emerging therapies
• Hypoglycemia Market Dynamics: Hypoglycemia market drivers and Hypoglycemia market barriers

Request for Sample PDF Report for Hypoglycemia Pipeline Assessment and clinical trials

Table of Contents

1. Hypoglycemia Report Introduction

2. Hypoglycemia Executive Summary

3. Hypoglycemia Overview

4. Hypoglycemia- Analytical Perspective In-depth Commercial Assessment

5. Hypoglycemia Pipeline Therapeutics

6. Hypoglycemia Late Stage Products (Phase II/III)

7. Hypoglycemia Mid Stage Products (Phase II)

8. Hypoglycemia Early Stage Products (Phase I)

9. Hypoglycemia Preclinical Stage Products

10. Hypoglycemia Therapeutics Assessment

11. Hypoglycemia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Hypoglycemia Key Companies

14. Hypoglycemia Key Products

15. Hypoglycemia Unmet Needs

16 . Hypoglycemia Market Drivers and Barriers

17. Hypoglycemia Future Perspectives and Conclusion

18. Hypoglycemia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting